A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Amgen
- 03 Apr 2018 Planned initiation date changed from 26 Mar 2018 to 30 May 2018.
- 05 Mar 2018 Planned primary completion date changed from 26 Mar 2021 to 2 Jul 2020.
- 19 Feb 2018 Planned End Date changed from 5 Feb 2021 to 26 Mar 2021.